Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Binding affinity to human NADK (345 to 365 residues) assessed as decrease in deuterium incorporation at 80 uM measured after 30 mins by HDX-MS analysis
Assay data:1 Tested
SummaryPubMed CitationRelated BioAssays by Target
Binding affinity to human NADK (155 to 164 residues) assessed as decrease in deuterium incorporation at 80 uM measured after 30 mins by HDX-MS analysis
Binding affinity to human NADK (410 to 418 residues) assessed as decrease in deuterium incorporation at 80 uM measured after 30 mins by HDX-MS analysis
Inhibition of NADK delta 95 kinase domain (unknown origin) at 80 uM measured after 30 mins by HDX-MS analysis
Assay data:1 Active, 1 Activity ≤ 1 µM, 1 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMPubMed CitationRelated BioAssays by Target
Non-competitive inhibition of N-terminal full length NADK (unknown origin) expressed in Escherichia coli BL21(DE3) cells by HDX-MS analysis
Assay data:1 Active, 1 Tested
SummaryCompounds, ActivePubMed CitationRelated BioAssays by Target
Binding affinity to N-terminal full length NADK (unknown origin) expressed in Escherichia coli BL21(DE3) cells assessed as dissociation constant by surface plasmon resonance assay
Inhibition of NADK (unknown origin) by HPLC analysis
Assay data:2 Tested
Inhibition of human NADK by HPLC analysis
Assay data:2 Active, 4 Tested
RNAi screen for vemurafenib enhancer genes in BRAFV600 melanoma - Primary Screen
Assay data:790 Active, 18119 Tested
Summary
Inhibition of human NADK expressed in Escherichia coli BL21(DE3) assessed as reduction in NADP production at 250 uM using NAD as substrate by glucose-6-phosphate dehydrogenase coupled enzyme based spectrophotometric method relative to control
Inhibition of human NADK expressed in Escherichia coli BL21(DE3) assessed as reduction in NADP production at 500 uM using NAD as substrate by glucose-6-phosphate dehydrogenase coupled enzyme based spectrophotometric method relative to control
Inhibition of human NADK expressed in Escherichia coli BL21(DE3) assessed as reduction in NADP production at 400 uM using NAD as substrate by glucose-6-phosphate dehydrogenase coupled enzyme based spectrophotometric method relative to control
Assay data:3 Tested
Inhibition of human NADK expressed in Escherichia coli BL21(DE3) assessed as reduction in NADP production using NAD as substrate by glucose-6-phosphate dehydrogenase coupled enzyme based spectrophotometric method
Assay data:28 Tested
Primary screen of kinases in signalling pathway between Protease activated receptor 2 (PAR2) and the ion channels Transient receptor potential vanilloid-4 (TRPV4) in HEK293 cells
Assay data:91 Active, 714 Tested
A screen to identify synergistic combinations in colorectal cancer - Primary Screen (SW620)
Assay data:15 Active, 794 Tested
SummaryPubMed CitationRelated BioAssays by Depositor
A screen to identify synergistic combinations in colorectal cancer - Primary Screen (SNUC5)
Assay data:11 Active, 794 Tested
A screen to identify synergistic combinations in colorectal cancer - Primary Screen (HCT15)
Assay data:18 Active, 794 Tested
A screen to identify synergistic combinations in colorectal cancer - Primary Screen (CAR1)
Assay data:9 Active, 794 Tested
A screen to identify synergistic combinations in colorectal cancer - Primary Screen (HT55)
Assay data:20 Active, 794 Tested
A screen to identify synergistic combinations in colorectal cancer - Primary Screen (RCM1)
Assay data:13 Active, 794 Tested
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on